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Poly(ADP-ribose) polymerase (PARP) inhibitors are selectively cytotoxic in
cancer cells with defects in homologous recombination (HR) (e.g., due to
BRCA1/2 mutations). However, not all HR-deficient tumors efficiently
respond to PARP inhibition and often acquire resistance. It is therefore
important to uncover how PARP inhibitors induce cytotoxicity and
develop combination strategies to potentiate PARP inhibitor efficacy in
HR-deficient tumors. In this study, we found that forced mitotic entry
upon ATR inhibition potentiates cytotoxic effects of PARP inhibition
using olaparib in BRCA2-depleted and Brca2 knockout cancer cell line
models. Single DNA fiber analysis showed that ATR inhibition does not
exacerbate replication fork degradation. Instead, we find ATR inhibitors
accelerate mitotic entry, resulting in the formation of chromatin bridges
and lagging chromosomes. Furthermore, using genome-wide single-cell
sequencing, we show that ATR inhibition enhances genomic instability of
olaparib-treated BRCA2-depleted cells. Inhibition of CDK1 to delay mito-
tic entry mitigated mitotic aberrancies and genomic instability upon ATR
inhibition, underscoring the role of ATR in coordinating proper cell cycle
timing in situations of DNA damage. Additionally, we show that olaparib
treatment leads to increased numbers of micronuclei, which is accompanied
by a cGAS/STING-associated inflammatory response in BRCA2-deficient
cells. ATR inhibition further increased the numbers of cGAS-positive
micronuclei and the extent of cytokine production in olaparib-treated
BRCA2-deficient cancer cells. Altogether, we show that ATR inhibition
induces premature mitotic entry and mediates synergistic cytotoxicity with
PARP inhibition in HR-deficient cancer cells, which involves enhanced
genomic instability and inflammatory signaling.
Abbreviations
53BP1, TP53-binding protein-1; ATR, ataxia telangiectasia and Rad3-related; BRCA1, breast cancer 1, early onset; BRCA2, breast cancer 2,
early onset; CCL5, C-C motif chemokine-5; CDK1, cyclin-dependent kinase-1; cGAS, cyclic GMP-AMP synthase; CI, combination index; DSB,
double-stranded break; EMI1, early mitotic inhibitor-1; FANCD2, Fanconi anemia group D2; GAPDH, glyceraldehyde-3-phosphate
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1. Introduction
BRCA1 (breast cancer, early onset 1) and BRCA2
(breast cancer, early onset 2) are essential components
of the homologous recombination (HR) DNA repair
machinery, which repairs toxic DNA double-stranded
breaks (DSBs) (Thompson and Schild, 2001). Loss of
BRCA1 or BRCA2 results in genomic instability,
underscoring the essential role for HR in genome
maintenance (Evers et al., 2008). Importantly, muta-
tions in HR genes, including in BRCA2, result in a
highly increased lifetime risk to develop breast and
ovarian cancer (Wooster et al., 1994). Interestingly,
due to their DNA repair defect, BRCA-mutant tumors
show increased sensitivity to certain DNA-damaging
agents, including platinum-based chemotherapeutics.
Additionally, BRCA-mutant tumors are selectively
sensitive to inhibition of poly(ADP-ribose) polymerase
(PARP) (Bryant et al., 2005; Farmer et al., 2005),
which has led to the successful implementation of
PARP inhibitors as a treatment strategy for BRCA1
or BRCA2 mutant tumors (Audeh et al., 2010; Tutt
et al., 2010).
Poly(ADP-ribose) polymerase inhibition results in
DNA lesions during DNA replication through multiple
mechanisms. PARP1 is involved in repair of single-
strand DNA breaks (SSBs). SSBs can be converted
into DNA DSBs during replication, when they remain
unrepaired due to PARP inhibition (Bryant et al.,
2005; Farmer et al., 2005). More recently, the ability
of PARP inhibitors to kill HR-deficient cells was
shown to be related to the capacity of PARP inhibitor
to trap PARP molecules onto DNA. These trapped
PARP molecules subsequently lead to stalling and col-
lapse of replication forks, which creates a dependency
on functional HR for cellular survival (Murai et al.,
2012). In addition, PARP1 was shown to restrain
replication fork speed, which underlies disturbed repli-
cation kinetics upon PARP inhibition (Maya-Mendoza
et al., 2018).
Cancer cells lacking functional BRCA2 are defec-
tive in protecting nascent DNA from degradation at
stalled replication forks (Schlacher et al., 2011; Ying
et al., 2012) and cannot properly repair the DSBs
that result from forks collapse (Moynahan et al.,
2001). Typically, accumulation of DSBs leads to acti-
vation of the G2/M cell cycle checkpoint, which pre-
vents entry into mitosis (L€obrich and Jeggo, 2007).
Whether replication-born DNA lesions efficiently
trigger a G2/M checkpoint response remains unclear.
Accumulating evidence shows that unresolved repli-
cation lesions do not necessarily block mitotic entry
and are transmitted into mitosis, leading to mitotic
aberrancies (Chan et al., 2018, 2009; Naim et al.,
2013; Schoonen et al., 2017).
Indeed, PARP inhibition in BRCA1 or BRCA2-de-
fective cancer cells leads to increased levels of mitotic
aberrancies including chromatin bridges and micronu-
clei (Chan et al., 2018; Feng and Jasin, 2017; Laulier
et al., 2011). Notably, the presence of such mitotic
aberrancies upon PARP inhibition was strongly asso-
ciated with PARP inhibitor-induced cytotoxicity
(Chan et al., 2018). Interestingly, the micronuclei that
originate as a consequence of defective DNA repair,
including BRCA2 inactivation, were shown to activate
a cGAS/STING (cyclic GMP-AMP synthase/stimula-
tor of interferon genes)-dependent interferon response
(Bakhoum et al., 2018; Heijink et al., 2019; MacKen-
zie et al., 2017). Indeed, treatment of Brca1-defective
ovarian tumors with a PARP inhibitor was shown to
trigger cGAS/STING signaling and thereby sensitize
these tumors to PD-1 blockade treatment (Ding et al.,
2018).
Although HR-defective cancer cells show profound
sensitivity to PARP inhibition, multiple mechanisms
of acquired resistance have been described, including
genetic reversion of the BRCA1 or BRCA2 muta-
tions (Edwards et al., 2008; Norquist et al., 2011;
Sakai et al., 2008; Swisher et al., 2008), inactivation
of the 53BP1/shieldin pathway (Bunting et al., 2010;
Noordermeer et al., 2018), downregulation of EMI1
(early mitotic inhibitor-1) (Marzio et al., 2018;
Schoonen et al., 2017), or alterations at the levels of
PARP1/2 abundance or activity (Gogola et al., 2018;
Henneman et al., 2015; Liu et al., 2009; Murai
et al., 2012; Oplustilova et al., 2012; Pettitt et al.,
2018). It is therefore pivotal to find successful com-
bination strategies to potentiate PARP inhibitor effi-
cacy.
A potentially effective strategy to potentiate PARP
inhibitor-mediated cytotoxicity would be to target the
G2/M cell cycle checkpoint to force mitotic entry in
the presence of DNA lesions. Indeed, it was previously
demonstrated that progression through mitosis pro-
motes PARP inhibitor cytotoxicity in HR-deficient
cells (Schoonen et al., 2017) and that inactivation of
cell cycle checkpoint kinases, including ATR (ataxia
telangiectasia and Rad3-related), could potentiate the
cytotoxicity of PARP inhibition (Kim et al., 2017;
Michelena et al., 2018; Schoonen et al., 2017). Because
cell cycle checkpoint kinases have functions beyond
regulating the G2/M cell cycle checkpoint (Byun et al.,
2005; Domınguez-Kelly et al., 2011; Matthew and
Newport, 1998), in this study we investigated the role
of ATR inhibition in potentiating the effects of the
PARP inhibitor olaparib.
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2. Materials and methods
2.1. Cell culture
The HeLa human cervical cancer cell line was obtained
from ATCC (Manassas, VA, USA) (#CCL2). Human
retinal epithelium RPE-1 cells were obtained from Bob
Weinberg (MIT, Cambridge, MA, USA). HeLa and
RPE-1 cells were cultured in Dulbecco’s modified
Eagle’s medium (DMEM), supplemented with 10%
FBS, 50 unitsmL1 penicillin, 50 µgmL1 strepto-
mycin, and 5 µgmL1 insulin (Sigma, Saint Louis,
MO, USA), in a humidified incubator supplied with
5% CO2 at 37 °C. Cell lines were verified by STR pro-
filing (BaseClear, Leiden, the Netherlands). The
KB2P1.21 cell line was established from a mammary
tumor from K14cre;Brca2F11/F11;p53F2-10/F2-10 mice as
described previously (Evers et al., 2008). The
KB2P1.21R1 cell line was created by the stable intro-
duction of an iBAC, containing the full-length mouse
Brca2 gene, into the KB2P1.21 cell line (Evers et al.,
2008). The K14cre;Brca2wt/wt;p53F2-10/F2-10 cell line
KP3.33 was obtained from Jos Jonkers (NKI, Amster-
dam, the Netherlands). All murine cell lines were cul-
tured in DMEM/F-12 medium, supplemented with
10% FBS, 50 unitsmL1 penicillin, 50 µgmL1 strep-
tomycin, 5 µgmL1 insulin (Sigma), 5 ngmL1 epi-
dermal growth factor (Life Technologies, Carlsbad,
CA, USA), and 5 ngmL1 cholera toxin (Gentaur,
Kampenhout, Belgium), at 37 °C under hypoxic condi-
tions (1% O2, 5% CO2).
2.2. MTT assays
HeLa, KB2P1.21, and KB2P1.21R1 tumor cell lines
were plated in 96-well plates. HeLa were plated at
2000 cells per well, and KB2P1.21 and KB2P1.21R1
were plated at 1200 cells per well. Cells were first
grown for 3 or 24 h and were subsequently treated
with the indicated concentrations of olaparib and
VE-821 for 3 days. Methyl-thiazol tetrazolium (MTT)
was added to cells at a concentration of 5 mgmL1
for 4 h, after which culture medium was removed
and formazan crystals were dissolved in DMSO.
Absorbance values were determined using a Bio-Rad
(Hercules, CA, USA) Benchmark III Biorad microti-
ter spectrophotometer at a wavelength of 520 nm.
Viability was determined by comparing absorbance
values to those of DMSO-treated cells. Experiment
was performed in triplicate. Graphs show representa-
tive experiments, which were performed at least
twice.
2.3. RNA interference
For siRNA (small interference RNA) transfection,
siRNAs (Ambion Stealth RNAi; Thermo Fisher, Wal-
tham, MA, USA) targeting BRCA2 (sequence 1:
#HSS186121; and sequence 2: sequence #HSS101095)
or a siSCR (scrambled) control sequence (sequence
#12935300) were used at a final concentration of
40 nM. Transfections were performed with Oligofec-
tamine (Invitrogen, Carlsbad, CA, USA) according to
the manufacturer’s guidelines.
2.4. Western blotting
Cell lysis was performed using Mammalian Protein
Extraction Reagent (MPER; Thermo Scientific), supple-
mented with protease inhibitor and phosphatase inhibi-
tor (Thermo Scientific). Protein concentrations were
measured using a Bradford assay. Next, proteins were
separated by SDS/PAGE and transferred to polyvinyli-
dene fluoride (PVDF; Immobilon, Merck, Burlington,
MA, USA) membranes and blocked in 5% skimmed
milk (Sigma) in Tris-buffered saline (TBS) containing
0.05% Tween-20 (Sigma). Immunodetection was per-
formed with antibodies directed against BRCA2 (Cal-
biochem, Merck, Burlington, MA, USA; #OP95), PAR
(Trevigen, Gaithersburg, MD, USA; #4336-BPC-100),
phospho-ATR (thr1898; Millipore, Burlington, MA,
USA; #ABE462), STING (1 : 1000; Cell Signaling,
Danvers, MA, USA, #13647), cGAS (1 : 1000; Cell Sig-
naling; #15102S) IRF3 (1 : 1000; Cell Signaling;
#4302), p-IRF3 (1 : 100; Cell Signaling; #29047), and
b-actin (MP Biomedicals, Santa Ana, CA, USA;
#69100). Horseradish peroxidase (HRP)-conjugated sec-
ondary antibodies (DAKO, Glostrup, Denmark) were
used for visualization using chemiluminescence (Lumi-
Light; Roche Diagnostics, Basel, Switzerland) on a Bio-
Rad bioluminescence device, equipped with QUANTITY
ONE/CHEMIDOC XRS software (Bio-Rad).
2.5. Immunofluorescence microscopy
HeLa, KB2P1.21, and KB2P21R1 cells were seeded on
glass coverslips in 6-well plates. When indicated, HeLa
cells were transfected with siRNAs for 48 h, of which
the final 24 h included treatment with olaparib
(0.5 µM) and/or VE-821 (1 µM) for 24 h as indicated.
For DNA bridge, micronuclei, cGAS (Cell Signaling;
#15102), or RAD51 (GeneTex, Irvine, CA, USA;
GTX7023) staining, cells were fixed using 4%
formaldehyde in PBS and subsequently permeabilized
for 5 min in PBS with 0.1% Triton X-100. For
FANCD2 (Novusbio, Centennial, CO, USA; NB100-
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182) and c-H2AX (Millipore; 05-636) staining, cells
were treated for 60 s with PEM [100 mM PIPES (pH
6.9), 1 mM MgCl2, and 10 mM EGTA]. Next, cells
were simultaneously fixed and permeabilized [20 mM
PIPES (pH 6.8), 0.2% Triton X-100, 1 mM MgCl2,
10 mM EGTA, 4% paraformaldehyde] for 10 min at
room temperature. Cells were then incubated with cor-
responding Alexa-488- or Alexa-647-conjugated sec-
ondary antibodies and counterstained with DAPI
(Sigma). For analysis of DNA damage response com-
ponents, prophase and pro-metaphase cells were
included for scoring, specifically mitotic cells with con-
densed chromosome, but prior to metaphase align-
ment. For analysis of chromatin bridges and lagging
chromosomes, anaphase and telophase cells were dis-
tinguished based on a-tubulin staining (Cell Signaling;
#2125). Images were acquired on a Leica DM6000B
microscope using a 639 immersion objective (PL S-
APO, numerical aperture: 1.30) with LAS-AF software
(Leica, Wetzlar, Germany).
2.6. Cytokine analysis
To analyze excreted CCL5 levels, KB2P1.21 and
KB2P1.21R1 tumor cell lines cells were treated with
0.5 µM olaparib and/or 1 µM VE-821. Culture media
were collected after 24 h. Subsequently, CCL5 concen-
trations were determined using the mouse CCL5
ELISA kit (R&D Systems, Minneapolis, MN, USA
#MMR00) according to the manufacturer’s protocol.
2.7. DNA fiber analysis
For DNA fiber analysis, HeLa or RPE-1 cells were
pulse-labeled with CIdU (25 µM) for 60 min followed
by IdU (250 µM) for 60 min when indicated. Next,
cells were washed with warm medium and incubated
with hydroxyurea (HU, 5 mM) for 5 h. Cells were then
trypsinized and lysed in lysis buffer [0.5% SDS,
200 mM Tris (pH 7.4), 50 mM EDTA] on tilted micro-
scopy slides. Following DNA spreading, slides were
air-dried and fixed in methanol/acetic acid (3 : 1) for
10 min. For immunolabeling, slides with DNA spreads
were incubated in 2.5 M HCl for 1.5 h. Primary anti-
bodies used were rat anti-BrdU (1 : 1000; Abcam,
Cambridge, UK; Ab6326) for CldU detection and
mouse anti-BrdU (1 : 500; ExBio, Vestec, Czech
Republic; 11-286-C100) for IdU detection. Secondary
antibodies were incubated for 1 h and were then fur-
ther incubated with Alexa Fluor 488- or 647-conju-
gated secondary antibodies (1 : 500) for 1.5 h. Images
were acquired on a Leica DM-6000RXA fluorescence
microscope, equipped with Leica Application Suite
software. The lengths of CIdU and IdU tracks were
measured blindly using IMAGEJ software (NIH,
Bethesda, MD, USA). Two-sided Mann–Whitney tests
with 95% confidence intervals were used for statistical
analysis.
2.8. Cell cycle analysis
Cells were synchronized at G1/S phase using a double-
thymidine block. Specifically, cells were treated with
thymidine (2 mM; Sigma) for 17 h, washed twice with
prewarmed PBS, and incubated in prewarmed warm
medium for 9 h. Subsequently, cells were again incu-
bated in thymidine for 17 h, after which cells were
washed with PBS and released in prewarmed medium
containing olaparib (1 µM), VE-821 (1 µM), or both,
and collected at the indicated time points. When indi-
cated, cells were trapped in mitosis using a 16-h incu-
bation with nocodazole (100 ngmL1; Sigma). Cells
were then fixed in ice-cold ethanol (70%) for at least
16 h and were stained with phospho-histone-H3
(Ser10; Cell Signaling; #9701, 1 : 50) in combination
with Alexa-488-conjugated secondary antibodies
(1 : 200). DNA staining was performed using propid-
ium iodide in the presence of RNase. At least 10 000
events per sample were analyzed on a FACSCalibur
(Becton Dickinson, Franklin Lakes, NJ, USA). Data
were analyzed using FLOWJO software (Becton Dickin-
son).
2.9. RT-PCR
RNA was isolated from KB2P1.21R1, KB2P1.21, and
KP3.33 using Qiagen RNeasy kit (Qiagen, Hilden,
Germany), and a total of 0.5µg RNA was used as
input for cDNA preparation (iScriptTM). Subsequently,
16 ng cDNA was used for a quantitative PCR using
the SYBR Green PCR Master Mix (Applied Biosys-
tems, Foster City, CA, USA). Hypoxanthine-guanine
phosphoribosyltransferase (Hprt) and glyceraldehyde-
3-phosphate dehydrogenase (GAPDH) were used as
control. The following primers were used for Brca2:
exon 10–11 forward: gaagcaagtgcttttgaag and reverse:
cagaagaatctggtatacctg; and exon 18–19 forward: ctcct-
gatgcctgtgcacc and reverse: cacgaaagaaccccagcct.
2.10. Single-cell whole-genome analysis
HeLa cells were incubated in mild lysis buffer, and sin-
gle G1 nuclei were sorted into 96-well plates, using a
Hoechst/propidium iodide double staining. Illumina-
based library preparation was performed as described
previously (van den Bos et al., 2016), in an automated
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fashion using a Bravo automated liquid handling plat-
form (Agilent Technologies, Santa Clara, CA, USA).
Single-cell libraries were pooled and sequenced on an
Illumina NextSeq 500 sequencer (Illumina, San Diego,
CA, USA). Sequencing data were analyzed using ANEU-
FINDER software as described previously (Bakker et al.,
2016). Per sample and per bin, the modal copy number
state of siSCR control-treated cells was determined,
and bins that deviated from the modal copy number
state were identified. The genomic instability scores
were assessed per cell, by determining the fraction of
bins that deviate from the modal copy number for that
sample. All sequencing data have been deposited at
the European Nucleotide Archive under accession no.
PRJEB31290.
3. Results
3.1. PARP inhibitor treatment induces a
concentration-dependent G2 arrest
DNA lesions induced by PARP inhibitor treatment
can trigger a G2 cell cycle arrest (Jelinic and Levine,
2014; Maya-Mendoza et al., 2018; Prasad et al., 2017;
Ray Chaudhuri et al., 2016; Rein et al., 2015). To
investigate the extent to which PARP inhibition
induces a G2 cell cycle arrest, BRCA2-depleted HeLa
cells were treated with increasing amounts of the
PARP inhibitor olaparib. Next, cells were trapped in
mitosis using the microtubule poison nocodazole, and
the percentages of cells in G2 and mitosis were quanti-
fied using the mitotic markers MPM2 and phospho-
H3-Ser10 (Fig. 1A,B and Fig. S1A). Interestingly,
increasing concentrations of olaparib decreased the
mitotic population in BRCA2-depleted cells, but not
in control cells (Fig. 1A and Fig. S1A). These data
indicate that PARP inhibition dose-dependently pro-
vokes a G2 arrest in BRCA2-depleted cells. Next, we
wanted to determine whether PARP inhibition can
also provoke a G2-arrest in more clinically relevant
HR models. To this end, we used K14cre;Brca2del/del;
p53del/del mouse mammary tumor cells (further denoted
as Brca2/), together with an isogenic line in which
BRCA2 expression was reconstituted using an infec-
tious bacterial artificial chromosome (iBAC) contain-
ing the mouse Brca2 gene (denoted as Brca2iBAC)
(Evers et al., 2008, 2010). RT-PCR analysis showed
similar expression levels of Brca2 in Brca2iBAC cells
compared to wild-type control cells (denoted as
Brca2+/+), while Brca2/ cells did not express tran-
scripts containing Brca2 exons 10–11 (Fig. S1B). Addi-
tionally, Brca2/ cells failed to form irradiation-
induced Rad51 foci, which were rescued in Brca2iBAC
cells, indicative of HR deficiency and restoration,
respectively (Fig. S1C). Importantly, PARP inhibitor
treatment resulted in decreased percentages of mitotic
cells, in both Brca2/ and Brca2iBAC cells (Fig. S1D).
Combined, these data indicate that PARP inhibitor
treatment induces delayed G2/M progression in a
dose-dependent fashion.
To reveal more subtle effects of PARP inhibitor treat-
ment on cell cycle progression, BRCA2-depleted HeLa
cells were synchronized using a double-thymidine block
(Fig. 1C). Although BRCA2 depletion itself did not
induce a detectable difference in cell cycle progression
(Fig. 1C), addition of PARP inhibitor at the time of
release from thymidine resulted in a minor but repro-
ducible delay in mitotic entry (Fig. 1D–F). Notably,
treatment with 1 µM olaparib resulted in a minor G2
delay, and treatment with a high olaparib concentration
(10 µM) triggered a robust G2-arrest (Fig. S1E,F).
Fig. 1. ATR inhibition induces premature mitotic entry and is synergistically cytotoxic with PARP inhibition. (A) HeLa cells were transfected
with control (siSCR, #12935300) or BRCA2 (‘siBRCA2 #1’, #HSS186121) siRNAs for 24 h and subsequently treated with DMSO and/or
olaparib (1, 5, or 10 µM) 24 h prior to harvesting. Next, cells were treated with nocodazole (250 ngmL1) for 18 h. DNA content (propidium
iodine) and MPM2-Alexa-647 were assessed by flow cytometry on a Becton Dickinson FACSCalibur (Becton Dickinson). A minimum of
10 000 events were analyzed per sample. Averages and standard deviations of three biological replicates are shown (n = 3). P values were
calculated using two-tailed Student’s t-test. (B) Representative MPM2-Alexa-647 plots are shown of HeLa cells treated as described in panel
A. (C, D) HeLa cells were transfected with control or BRCA2 siRNAs for 24 h and subsequently incubated with thymidine (2 mM) for 17 h.
Cells were then released for 9 h in prewarmed growth media and again treated for 17 h with thymidine prior to release in growth media
supplemented with DMSO, olaparib (1 µM), and/or VE-821 (1 µM). Cells were harvested at the indicated time points for flow cytometry
analysis. DNA content (propidium iodine) and pH3-Ser10/Alexa-488 were assessed by flow cytometry on a Becton Dickinson FACSCalibur
(Becton Dickinson). A minimum of 10 000 events were analyzed per sample. Representative DNA plots are shown in panel C.
Representative phospho-Ser10-histone-H3 plots are shown in panel D. (E, F) Quantification of results of panel D. Averages and standard
deviations of three biological replicates are shown. P values were calculated using a two-tailed Student’s t-test. (G) HeLa cells were
transfected with control siRNAs or siRNAs targeting BRCA2 and were treated with the indicated concentrations of olaparib and/or ATR
inhibitor VE-821. Methyl-thiazol tetrazolium (MTT, 0.5 mgmL1) was added for 4 h, and viability was assessed by colorimetric
measurement. (H) Combination indices (CI) for HeLa cell treated as described in panel g were determined using COMPUSYN software
(Compusyn Inc., New York, NY, USA). (I) KB2P1.21 (‘Brca2/’) and KB2P1.21R1 (‘Brca2iBAC’) cells were treated and analyzed as described
in panel g. (J) CI for treatments in Brca2iBAC and Brca2/ cells were determined using COMPUSYN software.
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To test the involvement of G2/M checkpoint activa-
tion in the PARP inhibitor-induced G2 delay, we
focused on the ATR cell cycle checkpoint kinase. Pre-
viously, ATR was shown to delay mitotic entry in
response to DNA damage (Brown and Baltimore,
2003), as well as during unperturbed cell cycle (Lem-
mens et al., 2018; Saldivar et al., 2018). In line with
these reports, we observed accelerated entry into mito-
sis upon ATR inhibition using VE-821 in BRCA2-de-
pleted cells (Reaper et al., 2011), either alone (DMSO
versus VE-821, P = 0.0059) or when combined with
PARP inhibition (olaparib versus combined olaparib/
VE-821, P = 0.0027) (Fig. 1E,F and Fig. S1E,F).
These data indicate that ATR inhibition can be uti-
lized to promote premature mitotic entry of cells trea-
ted with PARP inhibitor.
3.2. PARP inhibition and ATR inhibition
synergistically induce cancer cell killing
To investigate whether accelerated mitotic entry upon
combined ATR and PARP inhibition results in
increased cytotoxicity, cells were treated with increas-
ing concentrations of olaparib and/or VE-821. In line
with earlier findings, PARP inhibition efficiently
reduced cell viability in BRCA2-depleted HeLa cells
and Brca2/ cells, whereas control cells were largely
insensitive to PARP inhibition (Fig. 1G–J and
Fig. S1G,H). When PARP inhibitor treatment was
combined with ATR inhibition, synergistic loss of via-
bility was observed in HR-proficient cells, which
underscores a requirement for ATR in HR (Wang
et al., 2004). Importantly, addition of ATR inhibition
increased the sensitivity of HR-deficient cells to PARP
inhibition, which is in line with previous observations
(Kim et al., 2017; Fig. 1G–J and Fig. S1G,H). Com-
bined ATR and PARP inhibition was synergistic at
the majority of data points, as judged by combination
index (CI) scores lower than 1 (Fig. 1H,J and
Fig. S1H). Of note, only at the lowest drug concentra-
tions CI index values were higher than 1, which can be
explained by the absence of cytotoxic effects at these
conditions. Combined, these data indicate that ATR
inhibition and PARP inhibition are synergistically
toxic.
3.3. ATR inhibition promotes mitotic entry in the
presence of DNA damage
We next investigated mechanisms that could underlie
the observed cytotoxic effects of combined ATR and
PARP inhibition. In line with an ATR-dependent
cell cycle delay in BRCA2-depleted cells (Fig. 1), we
found that PARP inhibition leads to ATR activation
in BRCA2-depleted cells, as assessed by ATR
autophosphorylation at Thr-1989 (Fig. S2A). In these
experiments, PARP was efficiently inhibited as
judged by a near-complete loss of PARylation
(Fig. S2A).
Next, we tested whether combined ATR and PARP
inhibition exacerbated the degradation of stalled repli-
cation forks, since ATR inhibition was previously
shown to destabilize stalled replication forks in PARP
inhibitor-resistant cells (Yazinski et al., 2017). To this
end, BRCA2-depleted HeLa cells were incubated with
the thymidine analog CldU to label nascent DNA at
replication forks and were subsequently exposed to
hydroxyurea (HU) to stall replication (Fig. 2A). In line
with expectations, either PARP inhibition or BRCA2
depletion resulted in substantial degradation of nascent
DNA at HU-stalled forks (Fig. 2B). Furthermore,
combined PARP inhibition and BRCA2 depletion fur-
ther enhanced degradation of stalled forks (Fig. 2B).
Surprisingly, however, when ATR and PARP were
simultaneously inhibited, fork degradation was rescued
(Fig. 2B). Notably, fork stabilization upon ATR inhi-
bition was observed in both control-depleted and
BRCA2-depleted cells (Fig. 2B). Interestingly, ATR
inhibition did not prevent fork degradation in
BRCA2-depleted cells, in the absence of PARP inhibi-
tion, indicating that ATR inhibition does not rescue
fork degradation per se (Fig. 2B). Of note, combined
inhibition of PARP (using AZD-2461) and ATR (us-
ing VE-821 or VE-822) in RPE-1 cells resulted in simi-
lar findings (Fig. 2C), underscoring that inhibition of
ATR does not exacerbate PARP inhibitor-induced
degradation of stalled replication forks.
Rather than further exacerbating replication-born
DNA lesions, ATR inhibition may promote prema-
ture mitotic entry in the presence of DNA lesions. To
this end, BRCA2-depleted HeLa cells were treated
with olaparib and/or VE-821 and stained for
FANCD2 (Fanconi anemia group D2) and c-H2AX
(Fig. 2D). Inhibition of ATR alone resulted in an
increased amount of FANCD2 foci—but not c-H2AX
foci—in prophase/pro-metaphase cells (Fig. 2E,F). In
contrast, PARP inhibition alone increased both c-
H2AX and FANCD2 foci (Fig. 2E,F). Combined
inhibition of ATR and PARP led to a significant fur-
ther increase in c-H2AX and FANCD2 foci present
in prophase/pro-metaphase cells, with a larger effect
size in BRCA2-depleted cells compared to control-de-
pleted cells (Fig. 2E,F). Taken together, combined
ATR and PARP inhibition results in premature mito-
tic entry in the presence of substantial amounts of
DNA lesions.
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3.4. ATR inhibition exacerbates PARP inhibitor-
induced mitotic aberrancies in BRCA2-deficient
cells
We previously reported that PARP inhibitor treatment
of BRCA2-depleted HeLa cells results in aberrant
chromosome segregation (Schoonen et al., 2017). In
line with this notion, combined PARP and ATR inhi-
bition was observed to result in increased mitotic
defects and mitotic catastrophe (Kim et al., 2017;
Michelena et al., 2018). However, how ATR inhibition
contributes to this phenotype mechanistically remains
elusive. To investigate whether premature mitotic entry
upon ATR inhibition further increases mitotic aber-
rancies, we analyzed chromosome segregation defects.
In line with previously published data (Schoonen
et al., 2017), BRCA2-depleted cells showed increased
































































































































































































Fig. 2. Combined ATR and PARP inhibition increases the amount of DNA damage in mitotic cells. (A) A schematic representation of
treatment is shown. HeLa cells were transfected with control (siSCR) or BRCA2 (siBRCA2 #1) siRNA for 24 h and pulse-labeled with CIdU
for 60 min and were then treated with HU (5 mM), olaparib (5 lM), and/or VE-821 (5 lM), as indicated, for 5 h. Cells were then lysed, and
DNA was spread into single fibers. Representative immunofluorescence images of CldU tracks are shown. (B) CldU track length of cells
from panel a was determined for 200 fibers per condition. P values were calculated using a two-tailed Mann–Whitney test. (C) RPE-1 cells
were pulse-labeled with CIdU for 60 min and were then treated with HU (5 mM), AZD-2461 (1 lM), and/or VE-821 (5 lM) or VE-822 (1 lM),
as indicated, for 3 h and analyzed as for panel B. P values were calculated using a two-tailed Mann–Whitney test. (D) HeLa cells were
transfected with control or BRCA2 siRNA for 24 h and were treated with olaparib (0.5 µM) and/or VE-821 (1 µM). Cells were fixed and
stained for c-H2AX (red) and FANCD2 (green) and counterstained with DAPI (blue). Representative immunofluorescence images are shown.
(E, F) Numbers of c-H2AX foci (panel E) and FANCD2 foci (panel F) per mitotic nucleus were analyzed (n = 75 cells per condition). P values
were calculated using a two-tailed Mann–Whitney test. Throughout the figure, ‘ns’ indicates not significant. Scale bar represents 10 µm.
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PARP inhibition (67% in olaparib-treated BRCA2-de-
pleted cells versus 17% in olaparib-treated control
cells) (Fig. 3A,B). Similarly, lagging chromosomes
were more frequent (53% in olaparib-treated BRCA2-
depleted cells versus 6% in olaparib-treated control
cells; Fig. S2B). Importantly, the majority of the ana-
phase chromatin bridges in BRCA2-depleted cells
remained unresolved (Fig. 3B).
Interestingly, when mitotic entry was accelerated in
BRCA2-depleted cells through ATR inhibition, chro-
matin bridge formation upon PARP inhibition was
exacerbated in anaphase (91% versus 67%) and
telophase (71% versus 55%) (Fig. 3B). Of note, com-
bined PARP and ATR inhibition also increased the
frequency of chromatin bridges as well as lagging
chromosomes in control-depleted cells (Fig. 3B and
Fig. S2B). Similar mitotic defects were observed upon
combined inhibition of PARP and ATR in Brca2/
mammary tumor cells (Fig. 3C and Fig. S2C). Specif-
ically, combined ATR and PARP inhibitor treatment
in Brca2/ cells increased chromatin bridges in ana-
phase (73% versus 53%) and telophase (65% versus
43%) and resulted in elevated levels of lagging chro-
mosomes (63% versus 51%; Fig. 3C and Fig. S2C).
Again, these effects were not limited to Brca2/
cells, as HR-proficient Brca2iBAC cells also showed
increased chromatin bridge formation in anaphase
(47% versus 21%) and telophase cells (39% versus
P = 0.0327
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Fig. 3. Combined PARP and ATR inhibition increases the amount of mitotic aberrancies. (A) HeLa cells were transfected with control
(siSCR) or BRCA2 (siBRCA2 #1) siRNA for 24 h and treated with olaparib (0.5 lM) and/or VE-821 (1 lM) for 24 h. Cells were fixed in
formaldehyde (4%) and stained for a-tubulin (red) and counterstained with DAPI (white). Representative immunofluorescence images are
shown. Scale bar represents 10 µm. (B) Percentages of chromatin bridge-positive cells (n = 25 events per condition, per experiment).
Averages and standard deviations of three biological replicate experiments are shown. P values were calculated using two-tailed Student’s
t-test. (C) Brca2iBAC cells and Brca2/ cells were treated and analyzed as described for panel a. Averages and standard deviations of three
biological replicate experiments are shown. P values were calculated using two-tailed Student’s t-test. Throughout the figure, ‘ns’ indicates
not significant.
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11%; Fig. 3C), as well as increased amounts of cells
with lagging chromosomes (46% versus 19%;
Fig. S2C). Although combined inhibition of ATR
and PARP resulted in an elevation of chromatin
bridges in both HR-proficient and HR-deficient cells,
the effects were stronger in BRCA2-depleted cells
(Fig. 3B,C).
3.5. Delayed mitotic entry prevents mitotic
aberrancies and genomic instability induced by
combined ATR and PARP inhibition
To corroborate that the increased formation of chro-
matin bridges upon ATR inhibition is due to premature
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Fig. 4. CDK1 inhibition prevents mitotic aberrancies and genomic instability induced by combined ATR and PARP inhibition. (A) HeLa cells
were transfected with siSCR or siBRCA2 (siBRCA2 #1) for 24 h and were treated as indicated with olaparib (0.5 lM), VE-821 (1 lM).
Simultaneously, the CDK1 inhibitor RO-3066 (10 lM) was added to cells for 24 h, to delay G2/M cell cycle transition. Subsequently, RO-
3066 was removed, and after 90 min, cells were fixed and stained for a-tubulin (red) and counterstained with DAPI (white). Percentages of
chromatin bridge-positive cells (n = 15 events per condition, per experiment). Averages and standard deviations of three biological replicate
experiments are shown. P values were calculated using two-tailed Student’s t-test. Throughout the figure, ‘ns’ indicates not significant. (B)
HeLa cells were treated as in panel a and were harvested and frozen in medium containing 20% DMSO after 24 h. Cells were lysed and
stained using Hoechst/PI, and single G1 nuclei were sorted. Genomic DNA was isolated from 46 single nuclei, and genomic libraries were
included depending on library quality. Each row represents a single cell. Genome-wide copy number plots were generated using the
AneuFinder algorithm (see Section 2). Modal copy number states per ~ 1-Mb bin are indicated: Green indicates modal copy number,
whereas red indicates deviation from modal copy. Summary plots of indicated treatments are shown. Original ploidy scores are shown in
Fig. S4. (C) Quantification of data from panel b, showing the fraction of bins per individual library deviating from the sample modal copy
number. Statistical significance was determined using a Wilcoxon rank sum test (Mann–Whitney).
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G2/M transition through inhibition of CDK1. As
expected, treatment with the CDK1 inhibitor RO-3306
resulted in an accumulation of cells containing 4n DNA
and adjourned mitotic entry (Fig. S3A,B). To test the
effects of delayed mitotic entry, CDK1 was inhibited
for 24 h, and cells were analyzed at 90 min after CDK1
inhibitor was washed out (Fig. 4A). Clearly, transient
CDK1 inhibition reduced the percentage of PARP inhi-
bitor-induced chromatin bridges in BRCA2-deficient
cells in anaphase (43% versus 67%) as well as in telo-
phase (29% versus 45%) (Fig. 4A), suggesting that
PARP inhibitor-induced DNA lesions are more effi-
ciently resolved when mitotic entry is delayed. CDK1
inhibition caused the largest reduction in chromatin
bridge formation in cells cotreated with PARP and
ATR inhibitors (anaphase: 47% versus 86%; telophase:
31% versus 55%) (Fig. 4A). Notably, CDK1 inhibition
also reduced the numbers of lagging chromosomes
(Fig. S3C). Taken together, our findings show that
ATR inhibition increases unresolved PARP inhibitor-
induced DNA lesions in mitosis, at least in part, due to
accelerated mitotic entry.
Since combined inhibition of PARP and ATR
induces anaphase chromatin bridges and lagging chro-
mosomes (Fig. 3 and Fig. S2B,C), we next investigated
the impact of this treatment on genome integrity. To
this end, low-coverage single-cell whole-genome
sequencing (scWGS) was performed (Fig. S4) (Bakker
et al., 2016; van den Bos et al., 2016). Control HeLa
cells showed some degree of genomic instability, and
BRCA2 depletion did not significantly exacerbate levels
of genomic instability and ensuing heterogeneity within
the time frame of this experimental setup (Fig. 4B,C).
ATR inhibition alone led to minor elevation of genomic
instability in BRCA2-depleted cells, whereas olaparib
treatment resulted in widespread focal copy number
alterations (Fig. 4B,C). In line with our observation
that combined ATR and PARP inhibition in BRCA2-
depleted cells led to persisting chromatin bridges
(Fig. 3B), a significant increase in genomic instability
was observed in these cells (Fig. 4B,C). Notably, CDK1
inhibition significantly reduced the levels of genomic
instability, underlining that premature entry induced by
ATR inhibition drives genomic instability in PARP
inhibitor-treated BRCA2-depleted cancer cells.
3.6. ATR inhibition aggravates PARP inhibitor-
induced formation of cGAS-positive micronuclei
formation in BRCA2-deficient cells
The micronuclei that result from BRCA2 inactivation
were recently shown to trigger a cGAS/STING-depen-
dent interferon response (Heijink et al., 2019). We
therefore assessed whether inhibition of ATR and
PARP would exacerbate the formation of cGAS-posi-
tive micronuclei and the cGAS/STING-dependent
interferon response. PARP inhibitor treatment resulted
in increased formation of micronuclei in BRCA2-de-
pleted HeLa cells (20% in siBRCA2 #1 and 23% in
siBRCA2 #2-transfected olaparib-treated HeLa cells
versus 2% in olaparib-treated control cells; Fig. 5A,B).
Combined ATR and PARP inhibition further
increased overall numbers of micronuclei as well as
cGAS-positive micronuclei in BRCA2-depleted HeLa
cells (P = 0.0112 and P = 0.0075, respectively;
Fig. 5B). Detection of cytoplasmic DNA by cGAS
leads to STING-dependent interferon signaling, which
includes upregulation of STING itself and the secre-
tion of pro-inflammatory cytokines (Ablasser et al.,
2013; Gao et al., 2013; Sun et al., 2013). In HeLa cells,
BRCA2-depletion did not alter STING expression
levels nor levels of downstream components of cGAS/
Fig. 5. Combined ATR and PARP inhibition increases the amount of cGAS-positive micronuclei. (A) HeLa cells were transfected with control
siRNA (siSCR) or siRNA against BRCA2 (siBRCA2 #1, #HSS186121 siBRCA2 #2, #HSS101095) for 24 h and treated with olaparib (0.5 lM)
and/or VE-821 (1 lM) for 24 h. Cells were fixed in formaldehyde (4%) and stained for cGAS (green) and counterstained with DAPI (blue).
Representative immunofluorescence images are presented. Scale bar represents 10 µm. (B) Percentages of cGAS-positive and micronuclei-
positive cells (n = 200 events per condition per experiment). Averages and standard deviations of five biological replicate experiments are
shown. P values were calculated using two-tailed Student’s t-test. (C) Brca2/ and Brca2iBAC were treated with olaparib (0.5 lM) and/or VE-
821 (1 lM) for 24 h. Cells were fixed in formaldehyde (4%) and stained for cGAS (green) and counterstained with DAPI (blue).
Representative immunofluorescence images are presented. Scale bar represents 10 µm. (D) Percentages of cGAS-positive and micronuclei-
positive cells (n = 200 events per condition per experiment). Averages and standard deviations of five biological replicate experiments are
shown. P values were calculated using two-tailed Student’s t-test. (E) Brca2/ and Brca2iBAC were treated as described in panel c. Cell
lysates were subsequently immunoblotted for cGAS, STING, phospho-IRF3, IRF3, and b-actin. (F) Quantification of data shown in panel e.
Ratios of STING/b-actin and p-IRF3/IRF3 were normalized to controls. Averages and standard deviations of three biological replicate
experiments are shown. P values were calculated using two-tailed Student’s t-test. (G) Brca2/ and Brca2iBAC cells were treated as
described in panel C, and the levels of CCL5 in media were determined. Data are normalized to Brca2iBAC and presented as averages and
standard deviations of six biological replicate experiments. P values were calculated using two-tailed Student’s t-test. Throughout the figure,
‘ns’ indicates not significant.
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STING signaling (Fig. S5A), in line with viral HPV
oncogenes in HeLa cells inactivating STING (Lau
et al., 2015). Therefore, we next assessed cGAS/
STING activation upon PARP and ATR inhibition in
Brca2/ cells. Combined inhibition of ATR and
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well as the numbers of cGAS-positive micronuclei in
both Brca2/ and Brca2iBAC cells (P = 0.0029 and
P = 0.0089, respectively; Fig. 5C,D). In HR-proficient
Brca2IBAC cells, an increased number of micronuclei
were observed upon PARP inhibition and combined
ATR/PARP inhibition (Fig. 5D). However, a much
larger increase was observed upon ATR and combined
ATR/PARP inhibition in Brca2/ cells (Fig. 5D). To
assess whether the increase in cGAS-positive micronu-
clei coincided with increased inflammatory signaling,
we next assessed STING levels as well as phosphoryla-
tion of IRF3 (interferon regulatory factor 3) (Fig. 5E).
We found a slight increase in p-IRF3 in Brca2/ cells
compared to Brca2IBAC cells, however not when PARP
and ATR inhibition were combined (Fig. 5E). Interest-
ingly, STING was more abundant in untreated
Brca2/ cells compared to Brca2iBAC (Fig. 5F), possi-
bly reflecting the consequences of HR deficiency of the
Brca2/ cells. To test whether the increased levels of
cGAS-positive micronuclei triggered a pro-inflamma-
tory cytokine response, we measured CCL5 (C-C motif
chemokine 5) levels in the supernatants of Brca2/
and Brca2iBAC cells (Fig. 5G). Indeed, CCL5 produc-
tion was elevated in Brca2/ compared to Brca2iBAC
(P = 0.0389). After 24 h of combined ATR and PARP
inhibition, we observed increased CCL5 secretion,
although this increase was not statistically significant
(Fig. 5G). A more pronounced increase in CCL5 secre-
tion was found after 72 h of combined inhibition of
PARP and ATR (Fig. S5B). Taken together, these
data show that combining PARP and ATR inhibitors
leads to elevated numbers of micronuclei and increased
CCL5 secretion.
4. Discussion
Although HR-deficient cancer cells were shown to be
profoundly sensitive to PARP inhibition, multiple
mechanisms of acquired resistance have been
described. Here, we show that ATR inhibition
enhances the effect of PARP inhibitors in BRCA2-de-
ficient cells by accelerating entry into mitosis in the
presence of DNA lesions. As a consequence, combined
targeting of ATR and PARP leads to elevated levels
of mitotic chromatin bridges, genomic instability,
micronuclei formation, and cGAS/STING-associated
inflammatory signaling.
Our data confirm that PARP inhibition-induced
DNA damage can trigger G2/M checkpoint activation
in HR-deficient cancer cells (Jelinic and Levine, 2014;
Maya-Mendoza et al., 2018; Prasad et al., 2017; Ray
Chaudhuri et al., 2016; Rein et al., 2015). Interestingly,
we also observed a delayed mitotic entry upon ola-
parib treatment in HR-proficient cells. Notably, using
the nocodazole trap assay, Brca2iBAC cells showed pro-
nounced G2 delay (Fig. S1E), whereas control-trans-
fected HeLa cells did not show delayed G2/M
progression (Fig. 1A). Likely, the degree to which cells
delay G2 progression upon PARP inhibition differs



















PARP+ATR inhibition in HR-deficient cancer cells
Fig. 6. Model depicting how combined inhibition of ATR and PARP in HR-deficient cells causes premature mitotic entry with ensuing mitotic
aberrancies, increased interferon responses, and cell death.
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reproducible delay in mitotic entry in HeLa cells is
only noticeable in a time-course analysis of synchro-
nized cells (Fig. 1E and Fig. S1E), but not using end-
point assays (Fig. 1A and Fig. S1C).
ATR inhibition was previously shown to sensitize
cancer cells to various DNA-damaging agents (Abu-
Sanad et al., 2015; Josse et al., 2014; Reaper et al.,
2011), including synergistic interactions between PARP
and ATR inhibition in HR-deficient tumors (Huntoon
et al., 2013; Kim et al., 2017). We show here that ATR
inhibition sensitizes HR-deficient cells to PARP inhibi-
tion by forcing premature mitotic entry in the presence
of DNA lesions. Specifically, we observed an increase in
mitotic FANCD2 foci, a proxy for under-replicated
DNA (Chan et al., 2009). These results are in agreement
with previous findings that ATR regulates the S-G2
transition and that ATR inhibition results in under-
replicated DNA (Saldivar et al., 2017). We reinstated a
G2/M delay through blockade of CDK1, which rescued
the effects of ATR inhibition on genomic stability in
PARP-inhibited BRCA2-depleted cells, reinforcing the
role of ATR as a cell cycle checkpoint kinase.
ATR also controls additional mechanisms, which
could contribute to the potentiating effects of ATR inhi-
bition toward PARP inhibitor-mediated cytotoxicity in
BRCA2-defective cells. For example, ATR inhibition
has been shown to sensitize PARP inhibitor-resistant
BRCA1 mutant cancer cells to PARP inhibition
through blocking protection of stalled replication forks
(Yazinski et al., 2017). However, we found that
increased fork degradation was not associated with ele-
vated levels of cell death. This finding is in accordance
with recent observations (Feng and Jasin, 2017) and
may be explained by a role for ATR/CHK1 signaling in
preventing EMI1-mediated degradation of RAD51
(Marzio et al., 2018). Specifically, RAD51 has been
shown to be required for reversal of stalled forks, an
essential step in fork degradation (Mijic et al., 2017).
Inhibition of ATR may lead to unscheduled RAD51
degradation (Marzio et al., 2018). Although ATR inhi-
bitor-mediated RAD51 destabilization will lead to a
further decrease in HR DNA repair in BRCA-mutant
cells, RAD51 destabilization could prevent fork degra-
dation, which would explain our observation that ATR
inhibition rescues fork degradation upon PARP inhibi-
tion in BRCA2-defective cells. Alternatively, the rescue
of fork degradation upon combined ATR and PARP
inhibition could be explained by a requirement for ATR
in the proper localization or activation of nucleases that
target stalled replication forks, including MRE11 (mei-
otic recombination 11), MUS81 (crossover junction
endonuclease MUS81), and DNA2 (DNA replication
ATP-dependent helicase/nuclease DNA2) (Ray
Chaudhuri et al., 2016; Rondinelli et al., 2017; Xu et al.,
2017). Furthermore, it was recently shown that loss of
p53 results in altered origin firing and differential
responses replication stress (Benedict et al., 2018), which
may underlie the observed differences in fork stability
between HeLa and RPE-1 cells upon ATR inhibition.
Cytosolic DNA as a result of genomic instability
has recently been reported to trigger a cGAS/STING-
dependent interferon response (MacKenzie et al.,
2017). In line with this notion, loss of BRCA2 has also
been reported to activate cGAS/STING (Heijink et al.,
2019). We observed that treatment of BRCA2-defec-
tive cells with PARP inhibitor increases mitotic defects
and results in elevated numbers of micronuclei. Impor-
tantly, the numbers of micronuclei, including cGAS-
positive micronuclei, increased upon ATR inhibition.
Recently, cytosolic DNA induced by olaparib treat-
ment in BRCA1-deficient tumors was shown to render
these tumors sensitive to PD-1 blockade treatment
(Ding et al., 2018). Moreover, antitumor effects of
PARP inhibitor treatment in BRCA-deficient triple-
negative breast cancers were shown to depend on
cGAS/STING and subsequent T-cell responses (Pan-
telidou et al., 2019). Based on our data, combining
ATR and PARP inhibition could be used to further
increase micronuclei formation and thereby enforce
the subsequent cGAS/STING-mediated inflammatory
response. Such combination treatment may be useful
in potentiating sensitivity toward immune checkpoint
inhibitor treatment.
5. Conclusions
Our data show that PARP inhibitor-induced replica-
tion lesions that are not resolved in a timely fashion
can lead to mitotic entry in the presence of DNA
lesions and ensuing mitotic aberrancies and cell death
(Fig. 6). Targeting the cell cycle checkpoint kinase
ATR can be utilized to induce premature mitotic entry
and thereby increase the cytotoxicity of PARP inhibi-
tors in HR-deficient tumor cells. Further research is
warranted to extrapolate these results to other cell
cycle checkpoint components (e.g., CHK1 and WEE1),
and to explore these combination treatments in order
to provoke inflammatory signaling, a key determinant
of response to immune checkpoint inhibitors.
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Fig. S1. PARP inhibition induces a dose-dependent
G2-arrest, which is abrogated by ATR inhibition. (A)
HeLa cells were transfected with control or BRCA2
(siBRCA2 #1’) siRNAs for 24 hours and subsequently
treated with DMSO, olaparib (1, 5, or 10 µM) 24
hours prior to harvesting. Next, cells were treated with
nocodazole (250 ng/ml) for 18 hours. DNA content
(propidium iodine) and pH3-Ser10/Alexa-647 were
assessed by flow cytometry on a Becton Dickinson
FACSCalibur (Becton Dickinson, Franklin Lakes, NJ,
USA). A minimum of 10,000 events were analyzed per
sample. Averages and standard deviations of 3 biologi-
cal replicates are shown (n = 3). P values were calcu-
lated using two-tailed Student’s t-test. (B) RNA of
Brca2+/+, Brca2/, and Brca2iBAC cells was isolated
and RT-PCR was performed using oligos directed to
Brca2 exons 10-11, Brca2 exons 18-19, Hprt, or Gapdh.
(C) Brca2/ and Brca2iBAC cells were irradiated (5
Gy) and fixed in formaldehyde (4%) after 4 hours.
Subsequently, cells were stained for c-H2AX (red) and
RAD51 (green) and counterstained with DAPI (blue).
Scale bar represents 10 µm. (D) Brca2/ and
Brca2iBAC cells were treated and analyzed as described
in panel A. (E/F) HeLa cells were transfected with
siBRCA2 or siSCR for 24 hours and subsequently
incubated with thymidine (2 mM) for 17 hours. Cells
were then released for 9 hours in prewarmed growth
media and again treated for 17 hours with thymidine
prior to release in growth media supplemented with
DMSO, olaparib (10 µM), and/or VE-821 (1 µM).
Cells were harvested at the indicated time points.
Phospho-Ser10-histone-H3/Alexa-488 was assessed by
flow cytometry on a Becton Dickinson FACSCalibur
(Becton Dickinson, Franklin Lakes, NJ, USA). A min-
imum of 10,000 events were analyzed per sample. (G)
HeLa cells were transfected with control siRNA
(#12935300) or BRCA2 siRNA (siBRCA2 #2) and
were treated with the indicated concentrations of ola-
parib and/or VE-821. Methyl-thiazol tetrazolium
(MTT) was added (final concentration: 0.5 mg/mL) for
4 hours, and viability was assessed by colorimetric
measurement. (H) Combination indices were deter-
mined using COMPUSYN software.
Fig. S2. Combined PARP and ATR inhibition
increases the amount of lagging chromosomes. (A)
HeLa cells were transfected with control siRNAs
(‘siSCR’, #12935300) or siRNAs targeting BRCA2
(‘siBRCA2 #1’ ‘siBRCA2 #2’) for 24 hours, and were
next treated with PARP inhibitor olaparib (1 lM) for
24 hours. Cell lysates were subsequently immunoblot-
ted for BRCA2, poly-(ADP-ribose) polymers (PAR),
phospho-ATR, and b-actin. (B) HeLa cells were trans-
fected with control siRNA (#12935300) or BRCA2
siRNA (siBRCA2 #1) for 24 hours and treated with
olaparib (0.5 µM) and/or VE-821 (1 µM), cells with
lagging chromosomes (panel c, n = 50 events per con-
dition, per experiment) were quantified. Averages and
standard deviations of 3 biological replicate experi-
ments are shown. P values were calculated using two-
tailed Student’s t-test. (C) Brca2/ and Brca2iBAC
cells were treated with olaparib (0.5 µM) and/or VE-
821 (1 µM), cells with lagging chromosomes (n = 50
events per condition per experiment) were quantified.
Averages and standard deviations of 3 biological repli-
cate experiments are shown. P values were calculated
using two-tailed Student’s t-test.
Fig. S3. CDK1 inhibition prevents induction of lag-
ging chromosomes upon combined PARP and ATR
inhibition. (A/B) HeLa cells were transfected with
siSCR or siBRCA2 for 24 hours, and were subse-
quently treated with the CDK1 inhibitor RO-3066 (10
lM) for 24 hours. RO-3066 was removed, and cells
were fixed after 90 minutes. DNA content (propidium
iodine) and MPM-2/Alexa-647 positivity were assessed
by flow cytometry on a Becton Dickinson FACSCal-
ibur (Becton Dickinson, Franklin Lakes, NJ, USA). A
minimum of 10,000 events were analyzed per sample.
(C) HeLa cells were transfected with siSCR or
siBRCA2 (siBRCA2 #1) for 24 hours and were treated
with as indicated with olaparib (0.5 lM), VE-821 (1
lM). Simultaneously, the CDK1 inhibitor RO-3066
(10 lM) was added to cells for 24 hours, to delay G2/
M cell cycle transition. Subsequently, RO-3066 was
removed and after 90 minutes, cells were fixed and
stained for a-tubulin (red) and counterstained with
DAPI (white). Percentages of lagging chromosomes
cells (n = 30 events per condition, per experiment).
Averages and standard deviations of 3 biological repli-
cate experiments are shown. P values were calculated
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using two-tailed Student’s t-test. Throughout the fig-
ure, ‘ns’ indicates not significant.
Fig. S4. CDK1 inhibition rescues genomic instability
induced by combined ATR and PARP inhibition.
HeLa cells were transfected with siSCR or siBRCA2
for 24 hours, and were subsequently treated with
DMSO, olaparib (0.5 µM), VE-821 (1 µM), and/or
RO-3306 (10 µM) as indicated for 24 hours. Cells were
subsequently harvested and frozen in medium contain-
ing 20% DMSO. Cells were lysed and stained using
Hoechst/PI, and single G1 nuclei were sorted. Geno-
mic DNA was isolated of 46 single nuclei per condi-
tion, and resulting genomic libraries were included
depending on library quality. Every row represents a
single cell. Genome-wide copy number plots were gen-
erated using the AneuFinder algorithm (see Materials
and Methods). Copy number states were calculated for
~1-Mb bins, and depicted by color coding.
Fig. S5. Combined ATR and PARP inhibition
increases secretion of CCL5. (A) HeLa cells were
transfected with control siRNAs (‘siSCR’, #12935300)
or siRNAs targeting BRCA2 (‘siBRCA2 #1’ or
‘siBRCA2 #2’) for 48 hours. Cell lysates were subse-
quently immunoblotted for cGAS, STING, p-IRF3,
IRF3, and b-actin. (B) Brca2/ and Brca2iBAC cells
were treated with olaparib (0.5 µM), VE-821 (1 µM)
for 24, 48 or 72 hours and levels of CCL5 in media
were determined. Data are normalized to 1000 cells.
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